National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
213
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

TABLE D-5.3 Morbidity and Mortality due to Primary Hepatocellular Carcinoma

 

Population at Risk (millions)

Incidence Rate (per 100,000)

Number of Cases=Number of Deaths

High HBV Risk

 

 

 

South and east Asia

1,516

20

303,200

Sub-Saharan Africa

407

30

122,100

Oceania

5

10

500

Moderate HBV Risk

 

 

 

Central Asia

1,146

10

114,600

North Africa

124

10

12,400

South America

397

5

19,850

Total

 

 

572,650

 

SOURCE: Francis, personal communication, 1985.

Cirrhosis

Incidence rates of cirrhosis as a complication of hepatitis B have not been well documented. Beasley et al. (1981) found in Taiwan that for every death due to PHC there were 0.43 deaths from HBsAg-positive cirrhosis. This rate was applied to all PHC deaths. Cirrhosis deaths were assumed to equal 25 percent of cirrhosis cases. Cirrhosis cases were assigned to category E. Table D-5.5 shows the disease burden estimates for cirrhosis resulting from hepatitis B. Table D-5.6 shows the total disease burden estimates for hepatitis B.

PROBABLE VACCINE TARGET POPULATION

In highly endemic areas, the goal of HBV vaccination is to prevent both infection and the chronic carrier state. Because most population members of these areas are at risk of infection, universal vaccination is required. Furthermore, infection in these areas often occurs early in life, so the age of immunization must be adjusted accordingly. For areas of the world where perinatal infection is common, the first dose of vaccine should be given at birth (with the addition of hepatitis B immunoglobulin [HBIG] if vaccine alone is not effective in preventing perinatal infection) and subsequent doses delivered later. This approach is practical in many Asian countries because a substantial proportion of mothers deliver their infants in medical facilities. For areas of the world where perinatal infection is not a major problem, vaccination could be given simultaneously with other infant vaccinations. Thus, HBV vaccination could be incorporated into the World Health Organization Expanded Program on Immunization (WHO-EPI), with administration at the earliest current time of vaccine delivery.

Page
213
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)